Targeted engagement of CTLA‐4 prevents autoimmune thyroiditis
Vasu, Chenthamarakshan, Gorla, Seema R., Prabhakar, Bellur S., Holterman, Mark J.
Published in International immunology (01.05.2003)
Published in International immunology (01.05.2003)
Get full text
Journal Article
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Powles, Thomas, Valderrama, Begoña P., Gupta, Shilpa, Bedke, Jens, Kikuchi, Eiji, Hoffman-Censits, Jean, Iyer, Gopa, Vulsteke, Christof, Park, Se Hoon, Shin, Sang Joon, Castellano, Daniel, Fornarini, Giuseppe, Li, Jian-Ri, Gümüş, Mahmut, Mar, Nataliya, Loriot, Yohann, Fléchon, Aude, Duran, Ignacio, Drakaki, Alexandra, Narayanan, Sujata, Yu, Xuesong, Gorla, Seema, Homet Moreno, Blanca, van der Heijden, Michiel S.
Published in The New England journal of medicine (07.03.2024)
Published in The New England journal of medicine (07.03.2024)
Get full text
Journal Article
Abstract OT1-02-04: Enfortumab vedotin 202: Phase 2 study of enfortumab vedotin for previously treated advanced solid tumors, including breast cancer
Ono, Makiko, Bruce, Justine Yang, Feinstein, Trevor, Muro, Kei, Derleth, Christina, Gorla, Seema, Wu, Chunzhang, Novik, Yelena
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Published in Cancer research (Chicago, Ill.) (15.02.2022)
Get full text
Journal Article
Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202
Swiecicki, Paul, Yilmaz, Emrullah, Rosenberg, Ari J., Fujisawa, Takao, Yang Bruce, Justine, Meng, Changting, Wozniak, Michele, Wang, Lu, Gorla, Seema Rao, Geiger, Jessica Lyn
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
EV-203: Phase 2 trial of enfortumab vedotin in patients with previously treated advanced urothelial carcinoma in China
Li, Siming, Shi, Yanxia, Dong, Haiying, Guo, Hongqian, Li, Yue, Kadeerbai, Haishan, Xu, Chenming, Kim, Eric, Lee, Sue, Gorla, Seema Rao, Zhang, Jun, Guo, Jun, Sheng, Xinan
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors
Bruce, Justine Yang, Pusztai, Lajos, Braiteh, Fadi S., Gorla, Seema Rao, Wu, Chunzhang, Baranda, Joaquina
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer
Swiecicki, Paul L, Yilmaz, Emrullah, Rosenberg, Ari Joseph, Fujisawa, Takao, Bruce, Justine Yang, Meng, Changting, Wozniak, Michele, Zhao, Yongyun, Mihm, Michael, Kaplan, Jason, Gorla, Seema, Geiger, Jessica L
Published in Journal of clinical oncology (31.10.2024)
Published in Journal of clinical oncology (31.10.2024)
Get full text
Journal Article
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
Honma, Yoshitaka, Swiecicki, Paul L., Rosenberg, Ari Joseph, Hanna, Glenn J., Yang Bruce, Justine, Fujisawa, Takao, Muro, Kei, Kaplan, Jason B., Gorla, Seema Rao, Liu, Shubin, Meng, Changting, Geiger, Jessica Lyn
Published in Journal of clinical oncology (10.08.2024)
Published in Journal of clinical oncology (10.08.2024)
Get full text
Journal Article
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202
Giordano, Antonio, Awan, Arif Ali Ali, Yang Bruce, Justine, Rugo, Hope S., Diamond, Jennifer Robinson, Novik, Yelena, Baranda, Joaquina Celebre, Muro, Kei, Ono, Makiko, Nanda, Rita, Kaplan, Jason, Gorla, Seema Rao, Liu, Shubin, Wozniak, Michele, Lee, Anthony, Traina, Tiffany A.
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial
Swiecicki, Paul, Rosenberg, Ari J., Hanna, Glenn J., Yang Bruce, Justine, Fujisawa, Takao, Honma, Yoshitaka, Muro, Kei, Kaplan, Jason, Gorla, Seema Rao, Liu, Shubin, Meng, Changting, Geiger, Jessica Lyn
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202
Muro, Kei, Feinstein, Trevor, Baranda, Joaquina Celebre, Bonta, Ioana, Kitazono, Satoru, Gersten, Todd A., Gandhi, Leena, Kudo, Toshihiro, Kaplan, Jason, Gorla, Seema Rao, Liu, Shubin, Wozniak, Michele, Lee, Anthony, Patil, Tejas
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202
Muro, Kei, Chin, Keisho, Maron, Steven Brad, Braiteh, Fadi S., Mitani, Seiichiro, Hara, Hiroki, Kuboki, Yasutoshi, Mulcahy, Mary F, Baranda, Joaquina Celebre, Gardner, Faithlore Patrice, Jin, Ning, Hamauchi, Satoshi, Kaplan, Jason, Gorla, Seema Rao, Liu, Shubin, Wozniak, Michele, Meng, Changting, Kondo, Shunsuke
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
Van Der Heijden, Michiel Simon, Powles, Thomas, Gupta, Shilpa, Bedke, Jens, Kikuchi, Eiji, De Wit, Ronald, Galsky, Matt D., Duran, Ignacio, Necchi, Andrea, Retz, Margitta, Yu, Evan Y., Hoffman-Censits, Jean H., Iyer, Gopa, Park, Se Hoon, Su, Wen-Pin, Parmar, Hema, Guan, Xuesong, Gorla, Seema Rao, Homet Moreno, Blanca, Valderrama, Begoña Pérez
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104)
Kamat, Ashish M., Lotan, Yair, Roupret, Morgan, Steinberg, Gary D., Inman, Brant A., Powles, Thomas, Redorta, J. Palou, Porten, Sima P., Kulkarni, Girish S., Uchio, Edward M., Gorla, Seema Rao, Haas, Gabriel P., Yu, Yao, Chia, Yen Lin, Birrenkott, Matthew, Kates, Max R.
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer
Oza, Amit, Kaye, Stanley, Van Tornout, Jan, Sessa, Cristiana, Gore, Martin, Naumann, R. Wendel, Hirte, Hal, Colombo, Nicoletta, Chen, Jihong, Gorla, Seema, Poondru, Srinivasu, Singh, Margaret, Steinberg, Joyce, Yuen, Geoff, Banerjee, Susana
Published in Gynecologic oncology (01.05.2018)
Published in Gynecologic oncology (01.05.2018)
Get full text
Journal Article
A predictive model for the development of hormone-responsive breast cancer
Gorla, Seema Rao, Hou, Nanjiang, Acharya, Simbi, Rademaker, Alfred, Khan, Seema, Staradub, Valerie, Morrow, Monica
Published in Annals of surgical oncology (01.01.2005)
Published in Annals of surgical oncology (01.01.2005)
Get full text
Journal Article